retatrutide.md Blog

Retatrutide targets three hormone receptors instead of two, producing the largest weight loss seen in clinical trials. Here's how it compares to tirzepatide and what's ahead.

retatrutide.md provides a 2026 update on retatrutide clinical trials — phase 3 progress, expected approval timeline, and how results compare to tirzepatide.

retatrutide.md reviews the known side effects from phase 2 trials and what patients should watch for as phase 3 data emerges.

retatrutide.md explains the science behind triple agonist medications — what each receptor does and why targeting three pathways produces unprecedented weight loss.

retatrutide.md explores how retatrutide's unprecedented liver fat reduction could change treatment for the 100+ million Americans with fatty liver disease.

retatrutide.md previews every major obesity medication in development — from triple agonists to oral GLP-1s to amylin combinations.

Lilly plans to file with the FDA in Q1 2027, which puts the earliest realistic decision in 2028. Here is every Phase 3 readout so far and what still has to happen first.

TRIUMPH tested retatrutide against two obesity complications directly: it cut the apnea-hypopnea index by up to 36.1 events per hour and reduced WOMAC knee pain by up to 4.5 points. Here is the data, and what is still missing.

TRIUMPH-1 averaged 19.0% on 4 mg, 25.9% on 9 mg, and 28.3% on 12 mg at 80 weeks. Here is every dose and trial number, how it compares to Wegovy and Zepbound, and what the averages hide.

No. Retatrutide is unapproved everywhere, the FDA says it cannot be compounded, and tests of similar gray-market GLP-1 vials found 7.7% purity and endotoxin in every sample.

Retatrutide hit three receptors and 28.3% weight loss at 80 weeks in Phase 3. Semaglutide hit one receptor and 14.9% in STEP 1. Only one is approved today.

Retatrutide is investigational, so it has no price or coverage yet. Lilly plans an FDA filing in Q1 2027. Here is what the approved rivals cost today.

Phase 2 tested 1, 4, 8 and 12 mg weekly (up to 24.2% weight loss at 48 weeks). Phase 3 TRIUMPH uses 4, 9 and 12 mg from a 2 mg start. Not dosing advice.

Retatrutide's only published DXA substudy showed fat mass fell up to 26.1%, with a lean-loss share like other obesity drugs. No TRIUMPH body data yet.